MedTrace Logo

Sporozoite Challenge of Polyprotein Vaccinees

NCT00375128 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2007-10-19

No results posted yet for this study

Summary

This study examines the ability of two new malaria vaccines (FP9-PP and MVA-PP) to prevent the development of malaria infection after controlled exposure to the parasite. Volunteers for this trial will have received these vaccines in the preceding trial VAC027.1.

Conditions

Interventions

BIOLOGICAL

FP9-PP (FP9 polyprotein)

BIOLOGICAL

MVA-PP (Modified Virus Ankara polyprotein)

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • Wellcome Trust

    collaborator OTHER

  • Walter Reed Army Institute of Research (WRAIR)

    collaborator FED

  • European Vaccine Initiative

    lead OTHER

Principal Investigators

  • Adrian VS Hill, MA, BM BCh, DPhil, DM · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Completion
2007-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00375128 on ClinicalTrials.gov